DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: fingolimod

Summary for Generic Name: fingolimod

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Suppliers: see list1

Pharmacology for Ingredient: fingolimod

Clinical Trials for: fingolimod

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Status: Terminated Condition: Relapsing Remitting Multiple Sclerosis (RRMS)

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome
Status: Recruiting Condition: Rett's Syndrome

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Status: Completed Condition: Multiple Sclerosis

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
Status: Recruiting Condition: Relapsing Remitting Multiple Sclerosis

Safety and Efficacy of Fingolimod in MS Patients in China
Status: Not yet recruiting Condition: Multiple Sclerosis (Relapsing Remitting)

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
Status: Completed Condition: Multiple Sclerosis

An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
Status: Completed Condition: Relapsing Forms of Multiple Sclerosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes6,004,565<disabled>TREATMENT OF AUTOIMMUNE DISEASE
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes5,604,229<disabled>YTREATMENT OF AUTOIMMUNE DISEASE
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes8,324,283<disabled>
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes<disabled>ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc